InvestorsObserver
×
News Home

Should You Buy Onconova Therapeutics Inc (ONTX) Stock on Wednesday?

Wednesday, June 02, 2021 10:08 AM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Onconova Therapeutics Inc (ONTX) Stock on Wednesday?

Onconova Therapeutics Inc (ONTX) stock has fallen 2.13% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.

Sentiment Score - ,bearish
Onconova Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ONTX!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.

Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.

InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.

The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ONTX Stock Today?

Onconova Therapeutics Inc (ONTX) stock is trading at $6.90 as of 10:06 AM on Wednesday, Jun 2, an increase of $0.43, or 6.65% from the previous closing price of $6.47. The stock has traded between $6.45 and $6.95 so far today. Volume today is less active than usual. So far 225,456 shares have traded compared to average volume of 1,798,685 shares.

To see the top 5 stocks in the Biotechnology industry click here.

More About Onconova Therapeutics Inc

Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Click Here to get the full Stock Score Report on Onconova Therapeutics Inc (ONTX) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App